Study of UI-EWD (Nexpowder™) for Upper Gastrointestinal Bleeding
This study is comparing a new treatment, UI-EWD (Nexpowder™) hemostatic powder, to standard treatments for acute upper gastrointestinal bleeding. This type of bleeding can cause symptoms like vomiting blood (hematemesis) or dark, tarry stools (melena). Researchers want to see if UI-EWD is as effective as conventional methods like electrocautery or clips in stopping bleeding. You may be able to join if you are an adult aged 22 or older and have acute gastrointestinal bleeding from specific sources like ulcers or tumors. The main goal is to see if bleeding stops and doesn't restart within 7 days after treatment. The study aims to enroll 278 participants, but its current status is unclear.
- Study design
- This is a randomized controlled trial, meaning participants will be assigned by chance to receive either UI-EWD or conventional therapy. The study plans to enroll 278 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 7 days, looking for no further bleeding during that period after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
At a glance
Conditions
Where it's being run
14 sites across 11 statesStudy leadership
- Loren Laine, MD · STUDY_CHAIR · Yale University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- No further bleeding during the 7-day period after hemostatic treatment7 days
Further bleeding includes patients with persistent bleeding despite study-assigned endoscopic therapy or patients with recurrent bleeding